News
Safety of Long-Term Therapy with Bevacizumab in Oncological Patients
The angiogenesis inhibitor bevacizumab is typically administered long-term. Therefore, a study published in the journal The Oncologist deals specifically with its long-term safety and tolerability in patients with various types of solid tumors.
Effectiveness of Idarucizumab Reversal Effect
It is, of course, a great advantage if doctors have a specific substance available that counteracts…
Pain Management After Day Surgery
Effective pain control is a crucial part of recovery for patients after painful surgical…
Venetoclax Treatment Strategies in Patients with CLL
One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is the…
Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
Interesting real-world data have been brought by a study on the efficacy of lorlatinib in patients…
Interactive Case Study: AATD – Alpha-1-Antitrypsin Deficiency
We present a case study of a man who was 41 years old at the time of his first contact with a…
Probiotics as a Means to Reduce the Incidence of Streptococcus Mutans
Data from a prospective study examining the effects of probiotics on the oral microbiome show the…
Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis
How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data…
Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin
Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes…
Prim. MUDr. Gustáv Ondrejka: Biological treatment of asthma eliminates the need for systemic corticotherapy
Despite advances in the therapy of bronchial asthma, a portion of patients still do not achieve the…